Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-18
2009-08-18
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S300100, C548S302700, C548S309700, C514S385000
Reexamination Certificate
active
07576114
ABSTRACT:
Disclosed are compounds of the Formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9and R10are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 5128356 (1992-07-01), Naka et al.
patent: 5216003 (1993-06-01), Vazquez et al.
patent: 5250554 (1993-10-01), Naka et al.
patent: 5525625 (1996-06-01), Bridges et al.
patent: 5750545 (1998-05-01), Akahoshi et al.
patent: 5972980 (1999-10-01), Cornicelli et al.
patent: 6310060 (2001-10-01), Barrett et al.
patent: 6440966 (2002-08-01), Barrett et al.
patent: 6455582 (2002-09-01), Tecle
patent: 6469004 (2002-10-01), Barrett et al.
patent: 6506798 (2003-01-01), Barrett et al.
patent: 6534503 (2003-03-01), Dines et al.
patent: 6545030 (2003-04-01), Barrett et al.
patent: 6696440 (2004-02-01), Bridges et al.
patent: 6740649 (2004-05-01), Ott et al.
patent: 6803362 (2004-10-01), Carruthers et al.
patent: 6821963 (2004-11-01), Barrett et al.
patent: 6891066 (2005-05-01), Rewcastle et al.
patent: 7001905 (2006-02-01), Biwersi et al.
patent: 7030119 (2006-04-01), Barrett et al.
patent: 7067532 (2006-06-01), Boyle et al.
patent: 7102009 (2006-09-01), Patel et al.
patent: 7160915 (2007-01-01), Barrett et al.
patent: 7235537 (2007-06-01), Wallace et al.
patent: 7425637 (2008-09-01), Wallace et al.
patent: 2003/0224500 (2003-12-01), Ohren et al.
patent: 2004/0039208 (2004-02-01), Chen et al.
patent: 2004/0058934 (2004-03-01), Carruthers et al.
patent: 2004/0127395 (2004-07-01), Desai et al.
patent: 2004/0186111 (2004-09-01), Sun et al.
patent: 2005/0272740 (2005-12-01), Dorsch et al.
patent: 2007/0004713 (2007-01-01), Barlaam et al.
patent: 0694535 (1996-01-01), None
patent: 9843960 (1998-10-01), None
patent: 0040237 (2000-07-01), None
patent: 0041505 (2000-07-01), None
patent: 0068201 (2000-11-01), None
patent: 0105391 (2001-01-01), None
patent: 0105392 (2001-01-01), None
patent: 0105393 (2001-01-01), None
Hurley T. Brian
Lyssikatos Joseph P.
Marlow Allison L.
Wallace Eli M.
Array BioPharma Inc.
Hogan & Hartson LLP
Moore John R.
Shameem Golam M
LandOfFree
N3 alkylated benzimidazole derivatives as MEK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N3 alkylated benzimidazole derivatives as MEK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N3 alkylated benzimidazole derivatives as MEK inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4072647